[go: up one dir, main page]

JP2000508331A - 感染、炎症または免疫障害の影響を治療するためのオスモライトの使用 - Google Patents

感染、炎症または免疫障害の影響を治療するためのオスモライトの使用

Info

Publication number
JP2000508331A
JP2000508331A JP9536746A JP53674697A JP2000508331A JP 2000508331 A JP2000508331 A JP 2000508331A JP 9536746 A JP9536746 A JP 9536746A JP 53674697 A JP53674697 A JP 53674697A JP 2000508331 A JP2000508331 A JP 2000508331A
Authority
JP
Japan
Prior art keywords
osmolyte
cells
betaine
composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9536746A
Other languages
English (en)
Japanese (ja)
Inventor
ホイジンガー，デイーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2000508331A publication Critical patent/JP2000508331A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP9536746A 1996-04-12 1997-04-14 感染、炎症または免疫障害の影響を治療するためのオスモライトの使用 Pending JP2000508331A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9601395A SE9601395D0 (sv) 1996-04-12 1996-04-12 New therapeutic treatment 1
SE9601395-8 1996-04-12
PCT/EP1997/001862 WO1997038686A1 (fr) 1996-04-12 1997-04-14 Utilisation d'un osmolyte pour traiter les effets d'une infection, d'une inflammation ou d'une dysfonction du systeme immunitaire

Publications (1)

Publication Number Publication Date
JP2000508331A true JP2000508331A (ja) 2000-07-04

Family

ID=20402174

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9536746A Pending JP2000508331A (ja) 1996-04-12 1997-04-14 感染、炎症または免疫障害の影響を治療するためのオスモライトの使用

Country Status (7)

Country Link
EP (1) EP0910361A1 (fr)
JP (1) JP2000508331A (fr)
AU (1) AU2697197A (fr)
CA (1) CA2251204A1 (fr)
NO (1) NO984760D0 (fr)
SE (1) SE9601395D0 (fr)
WO (1) WO1997038686A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526789A (ja) * 2005-01-05 2008-07-24 アーメッド コトブ アブダラ，マグド タウリンの合成、生成及び医薬としての利用
JP2008537734A (ja) * 2005-03-12 2008-09-25 ビトップ アクツィエンゲゼルシャフト フュール ビオテヒニシェ オプティミールング 経口で用いられる適合溶質を含む薬剤

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
AUPO821097A0 (en) * 1997-07-25 1997-08-14 Cultor Ltd. A prophylactic
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
NZ512383A (en) * 1998-12-22 2003-05-30 Univ North Carolina Use of osmotic agents in the treatment of airway diseases and for the delivery of airway drugs
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
EP1272201B1 (fr) * 2000-04-12 2004-11-24 Bitop Aktiengesellschaft Für Biotechnische Optimierung Utilisation de solutes compatibles en tant que substances aux proprietes de piegeage de radicaux
WO2002013813A1 (fr) * 2000-08-11 2002-02-21 The Lawson Health Research Institute Inhibition du dysfonctionnement des îlots de langerhans et de troubles autoimmunes, et compositions à cet effet
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
WO2006050581A2 (fr) 2004-11-10 2006-05-18 Jallal Messadek Betaine en tant qu'agent de lutte contre des maladies transmises par des arthropodes ou des moustiques
EP2242489A1 (fr) 2005-02-15 2010-10-27 Jallal Messadek Compositions therapeutiques combinees et leurs procedes d utilisation
CA2650556A1 (fr) 2005-04-27 2006-11-02 Jallal Messadek Combinaisons insuliniques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3728444A (en) * 1971-04-28 1973-04-17 Stanley Drug Products Inc Method and compositions for inducing resistance to bacterial infections
AU7584891A (en) * 1990-03-19 1991-10-21 Brigham And Women's Hospital Treatment of osmotic disturbance with organic osmolytes
AU641529B2 (en) * 1990-07-30 1993-09-23 Bloomfield D.A. Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions
TW282398B (fr) * 1993-12-22 1996-08-01 Bristol Myers Squibb Co
US5516798A (en) * 1994-10-11 1996-05-14 North Carolina State University Method for treating diarrhea and a composition therefor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526789A (ja) * 2005-01-05 2008-07-24 アーメッド コトブ アブダラ，マグド タウリンの合成、生成及び医薬としての利用
JP2008537734A (ja) * 2005-03-12 2008-09-25 ビトップ アクツィエンゲゼルシャフト フュール ビオテヒニシェ オプティミールング 経口で用いられる適合溶質を含む薬剤

Also Published As

Publication number Publication date
CA2251204A1 (fr) 1997-10-23
NO984760L (no) 1998-10-12
WO1997038686A1 (fr) 1997-10-23
EP0910361A1 (fr) 1999-04-28
NO984760D0 (no) 1998-10-12
AU2697197A (en) 1997-11-07
SE9601395D0 (sv) 1996-04-12

Similar Documents

Publication Publication Date Title
CA2807787C (fr) Compositions de hmb et leurs utilisations
Enomoto et al. Development of a new, simple rat model of early alcohol‐induced liver injury based on sensitization of Kupffer cells
Robson et al. 11β-Hydroxysteroid dehydrogenase type 2 in the postnatal and adult rat brain
Derwahl et al. Multinodular goitre:‘much more to it than simply iodine deficiency’
Chan et al. The protective role of natural phytoalexin resveratrol on inflammation, fibrosis and regeneration in cholestatic liver injury
JP2000508331A (ja) 感染、炎症または免疫障害の影響を治療するためのオスモライトの使用
Hwang et al. DHA blocks TPA-induced cell invasion by inhibiting MMP-9 expression via suppression of the PPAR-γ/NF-κB pathway in MCF-7 cells
Chen et al. Low-protein diets supplemented with glutamic acid or aspartic acid ameliorate intestinal damage in weaned piglets challenged with hydrogen peroxide
Li et al. Protein phosphatase-1 in the kidney: evidence for a role in the regulation of medullary Na (+)-K (+)-ATPase
Li et al. Sialic acid exerts anti-inflammatory effect through inhibiting MAPK-NF-κB/AP-1 pathway and apoptosis in ulcerative colitis
JP2000508651A (ja) 虚血を原因とする合併症を治療する医薬を製造するためのオスモライトの使用
Shi et al. Bone marrow mesenchymal stem cell‐derived exosomes reduce insulin resistance and obesity in mice via the PI3K/AKT signaling pathway
Cammarata et al. Osmoregulatory alterations in taurine uptake by cultured human and bovine lens epithelial cells
Baraldi et al. The combination of conjugated linoleic acid (CLA) and extra virgin olive oil increases mitochondrial and body metabolism and prevents CLA-associated insulin resistance and liver hypertrophy in C57Bl/6 mice
Yang et al. Neohesperidin dihydrochalbazone protects against septic acute kidney injury in mice
Porta et al. Effects of dietary protein on the liver of rats in experimental chronic alcoholism
Khan et al. Fish oil selectively improves heart function in a mouse model of lipid-induced cardiomyopathy
Hu et al. Polysaccharide extracted from Laminaria japonica delays intrinsic skin aging in mice
Kalant et al. Effect of pyrazole on the induction of fatty liver by chronic administration of ethanol
TWI849808B (zh) 藥物組成物及化療劑用於製備治療癌症之藥物的用途
JP2003526661A (ja) 閉経後の女性および下等動物における脂溶性ビタミンの腸吸収を増進する際の方法
Birkhahn et al. Parenteral monoacetoacetin and liver regeneration interaction after partial hepatectomy in the rat
EP1475090A1 (fr) Medicaments pour maladies mitochondriales
Sato et al. DNA Microarray Analysis of Effects of TSH, Iodide, Cytokines, and Therapeutic Agents on Gene Expression in Cultured Human Thyroid Follicles
Li Strain differences in ethylene glycol induced calcium oxalate crystal formation in kidney in F344 and Wistar rats